miR-125b在儿童AML中的表达及其反义寡核苷酸对白血病细胞的作用

目的: 研究儿童急性髓细胞白血病(AML)患者骨髓细胞中miR-125b的表达及miR-125b为靶标的反义寡核苷酸对人白血病细胞的作用。方法: 采用基因芯片和实时荧光定量PCR技术(qRT-PCR)检测儿童AML治疗前后骨髓细胞中miR-125b的表达。采用电转法将与miR-125b序列互补的反义寡核苷酸转染HL-60细胞,细胞计数试剂盒(CCK-8)检测转染后24 h、48 h、72 h、96 h细胞增殖情况。结果: 芯片结果显示miR-125b在儿童AML中表达明显增高,约为正常的12倍,qRT-PCR结果进一步证实了miR-125b在儿童AML中异常高表达,同时还发现miR-125b在儿童AML部分缓解的患者骨髓细胞中表达下降,在完全缓解患者骨髓细胞中降至正常水平。CCK-8结果显示,针对miR-125b的反义寡核苷酸能有效抑制白血病细胞的增殖,与对照组相比有显著差异(P<0.01)。结论: miR-125b在儿童AML中可能起"癌基因"作用,以miR-125b为靶标的反义寡核苷酸可能为儿童AML治疗提供新的方法。     

多发性骨髓瘤的免疫学研究

多发性骨髓瘤 (ｍｕｌｔｉｐｌｅｍｙｅｌｏｍａ ,ＭＭ )是发生在Ｂ细胞系统的恶性肿瘤。其特征是骨髓中浆细胞克隆性增殖并积聚 ,分泌单克隆的免疫球蛋白或其片段 (Ｍ蛋白 ) ,同时伴有广泛的溶骨病变或骨质疏松。作为一种代表性的免疫增殖性疾病 ,ＭＭ的免疫学研究一直受到血液学和免疫学工作者的关注 ,近年来该领域更是成果斐然 ,引人瞩目。1　骨髓瘤细胞的起源[1 ]Ｂ细胞发育、分化过程中的哪一个阶段发生恶变 ,继而进一步分化为恶性细胞 ,是ＭＭ临床和科研人员一直关注的焦点之一 ,概括起来有以下几种假设。1 1　造血干细胞　依据主要有…     

细胞粘附分子在多发性骨髓瘤发病机制中的作用

细胞粘附分子是一类介导细胞与细胞、细胞与细胞外基质间（ＥＣＭ）粘附作用的膜表面糖蛋白，一方面在生理上参与细胞的迁移、定位、增殖、分化等活动，另一方面在肿瘤的发生和转移等领域发挥着重要作用。在多发性骨髓瘤的发病过程中，细胞粘附分子与瘤细胞的穴居、存活、增殖以及髓外转移密切相关，瘤细胞表面粘附分子表达的改变可以判断病情及预后，针对细胞粘附分子的靶向治疗将成为多发性骨髓瘤免疫治疗的新方法     

SRS白血病病毒的分子生物学和反义脱氧寡核苷酸抗病毒作用

1986年程立等应用携有白血病病毒的SRS腹水瘤无细胞提取液在体外感染NIH/3T3细胞获得成功,在国内首先建成能连续传递的SRSV/3T3细胞系,为白血病病毒的深入研究提供了良好的材料。已对SRS白血病病毒     

hTR反义寡核苷酸对不同鼻咽癌细胞生长分化的影响

目的 :研究端粒酶反义寡核苷酸对鼻咽癌细胞生长分化的影响。方法 :脂质体介导反义寡核苷酸转染鼻咽癌CNE1和CNE2Z细胞株 ,用细胞体外增殖实验、免疫组织化学S P法 ,观察细胞生长分化的变化情况。结果 :针对端粒酶RNA模板区的反义寡核苷酸可抑制CNE1和CNE2Z细胞的增殖并呈剂量和时间依赖性 ,反义寡核苷酸组细胞角蛋白表达高于其它处理组及空白对照组 (P <0 0 1) ,细胞形态趋向分化成熟。结论 :端粒酶反义寡核苷酸可抑制鼻咽癌CNE1和CNE2Z细胞的生长 ,并促进细胞分化。     

Anti-miRNA-155反义寡核苷酸(AMOs)对腹膜成纤维细胞(FB)增殖的影响

目的探讨anti-mi RNA-155反义寡核苷酸(AMOs)对腹膜成纤维细胞(FB)增殖的作用及可能机制。方法大鼠腹膜FB细胞分为:实验组(anti-mi RNA-155 AMOs 50nmol/L)、阴性对照组(错义链50nmol/L)和空白对照组(PBS)。采用Lipofec-tamine2000作为载体分别转染各组原代培养大鼠腹膜FB细胞,应用real time PCR方法测定转染后mi RNA155水平,CCK8法检测转染后腹膜FB细胞增殖,transwell法检测转染后腹膜FB细胞迁移程度,Western blot检测转染后腹膜FB细胞NF-κB p65与PCNA水平。结果转染48 h后,实验组腹膜FB细胞的mi RNA-155水平,增殖和迁移比例明显低于阴性对照组和空白对照组(0.01),NF-κB p65、PCNA蛋白表达水平下调(0.05)。结论 mi RNA-155增加NF-κB p65表达的同时,促进腹膜FB细胞的增殖和迁移。     

全硫代反义寡核苷酸对脑胶质瘤细胞端粒酶活性作用

目的本研究采用针对人端粒酶hTR基因的反义寡聚脱氧核苷酸,探讨端粒酶反义寡聚脱氧核苷酸(antisense oligodeoxy nucleotides,ASODN)对脑胶质瘤HO-8910细胞端粒酶活性及细胞增殖的影响。方法本实验将互补于hTR模板区的全硫代修饰型反义寡核苷酸(PS-ASODN)经lipotap脂质体转染作用于脑胶质瘤细胞系C6,然后分别采用四甲基偶氮唑蓝(MTT)比色实验、酶联免疫吸附试验(ELISA)法和流式细胞术检测C6脑胶质瘤细胞的体外增殖、端粒酶活性、细胞凋亡和细胞周期的改变。结果经MTT法检测,PS-ASODN对C6细胞生长具有明显的抑制作用和诱导细胞凋亡,1.0μMPS-ASODN处理后24h细胞生长抑制率为12.93%,且随着时间的延长,抑制作用逐渐增强;给药72h对细胞生长抑制率达到最高,为50.81%,有相应的浓度依赖关系。ELISA法检测结果 ,0.5～1.5μM的PS-ASODN对C6细胞作用72h后端粒酶皆为阴性,表明PS-ASODN能够抑制端粒酶活性,对照组端粒酶皆为阳性。结论端粒酶PS-ASODN对体外培养的脑胶质瘤C6细胞的增殖有明显的浓度、时间依赖性抑制作用;抑制脑胶质瘤C6的端粒酶活性和诱导C6脑胶质瘤细胞发生凋亡,可能是端粒酶PS-ASODN抑制C6细胞增殖的主要机制。     

天麻素对激活小胶质细胞miR-124和miR-155表达的影响

目的:研究天麻素对激活的小胶质细胞miR-124和miR-155表达含量的影响。方法:分为体内实验和体外实验,体内实验：将新生3 d的SD大鼠随机分为假手术组(sham)、缺血缺氧模型组(HIBD)、缺血缺氧+天麻素干预组(G+HIBD),体外实验：将BV2细胞随机分为对照组(control)、氧糖剥夺组(OGD)、天麻素+氧糖剥夺组(G+OGD),real time RT-PCR检测大鼠胼胝体及BV2细胞miR-124和miR-155的表达变化。结果:体内、体外real time RT-PCR结果显示：与sham、control组相比,HIBD组大鼠胼胝体及OGD处理的BV2细胞、OGD组的miR-155表达水平升高,miR-124表达水平降低(P<0.05);使用天麻素干预后,miR-155表达水平降低,miR-124表达水平升高(P<0.05)。结论:天麻素能促进激活的小胶质细胞miR-124的表达,抑制miR-155表达,从而发挥其神经保护作用。     

可溶性syndecan-1 对人多发性骨髓瘤细胞体外的生物学作用

目的：研究可溶性ｓｙｎｄｅｃａｎ－１（ＣＤ１３８）分子对人多发性骨髓瘤（ＭＭ）细胞生长行为的影响及其机制。方法：用亲和层析法分离可溶性ｓｙｎｄｅｃａｎ－１;借助＾３Ｈ－ＴｄＲ掺入、间接免疫荧光、ＡＮＮＥＸＩＮ－Ｖ及ＰＩ标记分析ＭＭ细胞增殖、凋亡周期变化。结果：（１）从ＸＧ－２细胞培养上清中分离纯化得到分子量为６０ｋＤ左右的可溶性ｓｙｎｄｅｃａｎ－１分子;（２）可溶性ｓｙｎｄｅｃａｎ－１分子在体外能抑制ＸＧ－１增殖,阻滞细胞增殖停留在Ｇ２／Ｍ期。并介导其凋亡;ＦＧＦ、５％小牛血清、肝素酶Ⅲ可逆转一定浓度可溶性ｓｙｎ－ｄｅｃａｎ－１的作用,ＨＧＦ、ＶＥＧＦ和ＩＧＦ－１可部分逆转可溶性ｓｙｎｄｅｃａｎ－１分子对细胞的生长抑制作用;（３）ＩＬ－６及激发型抗ＩＬ－６Ｒ１３０（ｇｐ１３０）单抗对可溶性ｓｙｎｄｅｃａｎ－１ｗ     

反义myb寡核苷酸对内皮素诱导动脉平滑肌细胞增殖抑制作用的研究

合成反义和正义ｃ－ｍｙｂ１８－ｍｅｒ，分别导入培养的ＷＫＹ主动脉平滑肌细胞（ＳＭＣｓ），同时用内皮素诱导ＳＭＣｓ增殖。反义ｃ－ｍｙｂ寡核苷酸（ＯＤＮｓ）对内皮素诱导ＳＭＣｓ的抗细胞增殖抑制作用随浓度（６０μｍｏｌ·Ｌ－１～１２０μｍｏｌ·Ｌ－１）的增加而增加。用１２０μｍｏｌ·Ｌ－１反义ＯＤＮｓ抗细胞增殖能力随时间延长而下降。免疫组化显示受抑制细胞ｍｙｂ水平较同期对照组或正义ＯＤＮｓ组低。以上为反义ＯＤＮｓ抑制外源性生长因子或细胞因子诱导靶基因的高表达和细胞增殖提供了新的线索，同时为探讨癌基因表达调控与动脉ＳＭＣｓ增殖的关系提供了一种新方法。     

miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1

Background

Though the levels of diagnosis and treatment of multiple myeloma (MM) have been largely improved recent years, the prognosis of these patients remain unacceptable. It is urgent for us to discover the exact mechanism and determine some new indicators for MM. MiRNAs play a critical role in the occurrence and progression of cancers, including MM. MiR-26b-5p has been reported to be closely related to cells proliferation in human pulmonary cancer, hepatocellular carcinoma and so on.

miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4

miR-182 is a well-described oncogenic miRNA playing a crucial role in the development of many malignancies. However, the role of miR-182 in multiple myeloma (MM) remains unclear. Here, we demonstrate that adhesion of H929 and MM.1S cells to fibronectin could induce miR-182 expression and decrease PDCD4 expression. Furthermore, miR-182 was found to negatively regulate PDCD4 expression in H929 and MM.1S cells. In addition, PDCD4 down-regulation was required for cell adhesion-mediated drug resistance (CAM-DR). Intriguingly, miR-182 up-regulation could promote CAM-DR in H929 and MM.1S cells. Moreover, miR-182 up-regulation and PDCD4 down-regulation enhanced AKT phosphorylation at Ser473 in both H929 and MM.1S cells. Our data suggest that cell adhesion-mediated miR-182 up-regulation and PDCD4 down-regulation may confer drug resistance via enhancing AKT phosphorylation at Ser473.     

miR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma

Background: Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow and microRNAs play a crucial role in its tumorigenesis and development. The purpose of this study was to investigate the biological functions of miR-301a in MM. Methods: Quantitative real-time PCR was used to detect the expression level of miR-301a. Cell proliferation was assessed by MTT assay. Flow cytometry was performed to valuate cell apoptosis and cell cycle distribution. Moreover, luciferase reporter assay and western blot were conducted to determine the potential target of miR-301a in MM cells. Results: MiR-301a is significantly up-regulated in MM clinical bone marrow samples and cell lines compared with normal controls. Gain-of-function and loss-of-function studies in MM cell line U266 showed that miR-301a acts as an oncogene in MM by promoting cell proliferation and inhibiting apoptosis. Furthermore, a tumor suppressor gene, tissue inhibitor of metallopeptidases-2 (TIMP2) was identified as a direct target of miR-301a and knockdown of TIMP2 could mimic the effect of miR-301a in MM. Conclusions: MiR-301a promotes cell proliferation and inhibits apoptosis by direct targeting TIMP2 in MM, and miR-301a might represent a novel molecular in MM and may provide helpful therapeutic strategies for MM treatment.     

miR-155在肾结石患者血清和尿液中的表达及其临床意义

目的:血液和尿液中的miRNAs可能存在一种潜在的无创的能够预测慢性肾脏疾病的生物学标志物,在本研究中,我们将会研究肾结石患者血清和尿液中miR-155的表达水平.方法:选取2011年 8月~2012年8月间同济大学上海市第十人民医院泌尿外科收治的60例肾结石患者,以同期50例健康体检者作为对照,应用实时荧光定量PCR技术检测并比较肾结石患者和健康体检者血清和尿液miR-155的表达水平.同时计算出肾小球滤过率估算值(estimated glomerular filtration,eGFR),通过简单的回归分析,分析miR-155/eGFR 及miR-155/CRP表达水平之间的相关关系.结果: 肾结石患者血清和尿液miR-155的表达水平均显著高于对照组.eGFR与尿液中miR-155的表达水平呈负相关;CRP与尿液中miR-155的表达水平呈正相关.尿液中miR-155的表达水平同白细胞介素(IL)-1β、 IL-6和肿瘤坏死因子(TNF)-α的表达水平呈负相关,但同正常T细胞表达分泌的活性调节因子(regulated upon activation normal T-cell expression and secreted,RANTES)的表达水平呈正相关.结论:肾结石患者血清和尿液中miR-155的表达水平明显升高, miR-155表达水平的上调与eGFR下降和CRP升高有关.我们的研究结果表明miR-155通过调节炎症因子表达在肾结石的病理生理学中扮演重要的角色,有可能成为预测肾结石发病的生物学标志物.     

Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study

To explore biologic behaviors and disease relevance of microRNAs (miRNAs) in the development of active tuberculosis (ATB), we investigated the expression profile of Mycobacterium tuberculosis (MTB) purified protein derivative (PPD)-induced miRNAs to determine the specific miRNAs involved in the pathogenesis of ATB. The expression profile of miRNA under PPD challenge was first measured using microarray analysis in peripheral blood mononuclear cells isolated from ATB patients and healthy controls (HC). The remarkably reactive miRNAs were then validated in a larger cohort by quantitative real-time polymerase chain reaction (qRT-PCR). The receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic value of the determined PPD-responsive miRNAs. The potential targets for those miRNAs were also predicted by computational programs. Fourteen of 866 human miRNAs exhibited at least 1.8-fold difference in the ratio of expression level before and after stimulation with PPD between the ATB and HC groups. The qRT-PCR study validated the findings from microarray-based screening, in which miR-155 exhibited a fold change of 1.4 in the HC group and 3.7 in the ATB group upon PPD stimulation (p < 0.0001); miR-155* exhibited a fold change of 1.9 in the HC and 4.6 in the ATB group (p < 0.005). In ROC plots, the area under the curve was 0.8972 for miR-155 and 0.7945 for miR-155*. The background expression of these 2 microRNAs exhibited no differences between the ATB and HC groups. miR-155 and miR-155* exhibited characteristic expression by TB-specific antigen, suggesting that they can be potential diagnostic markers under the challenge of specific MTB antigens.     

miR-155 modulates the progression of neuropathic pain through targeting SGK3

This study aimed to illustrate the potential effects of miR-155 in neuropathic pain and its potential mechanism. Spragure-Dawley (SD) rats were used for neuropathic pain model of bilateral chronic constriction injury (bCCI) construction. Effects of miR-155 expression on pain threshold of mechanical stimuli (MWT), paw withdrawal threshold latency (PMTL) and cold threshold were analyzed. Target for miR-155 was analyzed using bioinformatics methods. Moreover, effects of miR-155 target gene expression on pain thresholds were also assessed. Compared with the controls and sham group, miR-155 was overexpressed in neuropathic pain rats (P<0.05), but miR-155 slicing could significantly decreased the pain thresholds (P<0.05). Serum and glucocorticoid regulated protein kinase 3 (SGK3) was predicted as the target gene for miR-155, and miR-155 expression was negatively correlated to SGK3 expression. Furthermore, SGK3 overexpression could significantly decreased the pain thresholds which was the same as miR-155 (P<0.05). Moreover, miR-155 slicing and SGK3 overexpression could significantly decrease the painthreshold. The data presented in this study suggested that miR-155 slicing could excellently alleviate neuropathic pain in rats through targeting SGK3 expression. miR-155 may be a potential therapeutic target for neuropathic pain treatment.     

miR-155-5p在宫颈癌血清中的表达及其对宫颈癌细胞的影响

 目的：检测miR-155-5p在不同宫颈疾病患者血清中的表达差异,并分析其对宫颈癌细胞增殖、细胞周期和凋亡的影响,探讨miR-155-5p在宫颈癌发生、发展中的可能作用机制。方法：采用SYBR GreenⅠ实时荧光定量PCR法,检测并分析比较miR-155-5p在不同宫颈疾病患者血清中的表达差异。利用miR-155-5p mimic或inhibitor提高或降低宫颈癌细胞中miR-155-5p的表达。CCK-8法和流式细胞术检测宫颈癌细胞的增殖、细胞周期和凋亡。结果：宫颈癌组血清中miR-155-5p的表达高于宫颈炎组和健康对照组（P<0.05）,宫颈上皮内瘤样病变组和宫颈癌组血清中miR-155-5p的表达差异无统计学意义（P>0.05）。与空白组、脂质体组和阴性对照组相比,转染100 nmol/L和200 nmol/L miR-155-5p mimic的SiHa细胞中,S期细胞比例升高,凋亡细胞比例降低（P<005）。转染100 nmol/L和200 nmol/L miR-155-5p inhibitor的SiHa细胞中,G2/M期细胞比例明显增多（P<005）。结论：(1)宫颈癌患者血清中miR-155-5p表达较健康对照人群上调,可能作为宫颈癌早期诊断的肿瘤分子标志物。(2)miR-155-5p对宫颈癌HeLa细胞增殖、细胞周期和凋亡无明显影响。(3)miR-155-5p可促进宫颈癌SiHa细胞进入S期,并抑制SiHa细胞凋亡,提示miR-155-5p可能在宫颈鳞癌发生、发展中起作用。     

Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation,invasion and migration of clear cell renal cell carcinoma

This study aimed to investigate the effect of blocking the MIR155HG/miR-155-5p/-3p axis on proliferation, invasion and migration of clear cell renal cell carcinoma. RT-qPCR was used to detect the expression of MIR155HG, miR-155-5p, miR-155-3p in clear cell renal cell carcinoma cell lines. To study the effects of blocking LncRNA MIR155HG and interfering with miR-155-5p and miR-155-3p on the biological function. The g proliferation of tumor was detected by CCK-8, and the cell invasion and migration abilities were detected by wound healing and transwell experiments. Western blot analyzed protein levels of KI67, PCNA, MMP2 and MMP9. Furthermore, TargetScan and miRDB were used to predict the co-target gene of miR-155-3p and miR-155-5p, and the functional analysis of co-target genes was performed using the DAVID. In the current research, the expression of MIR155HG was increased in ccRCC. Interference of MIR155HG inhibited the cellular functions of ccRCC cells, which was reversed by overexpression of miR-155-3p and miR-155-5p.In addition, MIR155HG interference repressed the expression of miR-155-5p and miR-155-3p in ccRCCs, while inhibition of miR-155-5p and miR-155-3p restrained the proliferation, invasion and migration of ccRCCs. Bioinformatics software analysis showed 13 co-targeting genes of miR-155-3p and miR-155-5p. Functional analysis presented that the target genes of miR-31-3p were involved in numerous of biochemical processes and pathways.Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation, invasion and migration of renal clear cell carcinoma, which provided a new method for early diagnosis and precise treatment of ccRCC.     

血管内皮生长因子基因反义核酸的设计及其对K562细胞增殖的影响

目的:试图用计算机设计并筛选出血管内皮生长因子(VEGF)的高效反义核酸;用实验方法研究VEGF反义核酸对K562细胞增殖的影响。方法:用RNAstructure(version3.7)软件,选择总自由能(overall△G₃₇)相对低的反义核酸,共计7条,长度18-20核苷酸,全硫代修饰;细胞培养72h,采用台盼蓝拒染法观察存活细胞,用ELISA法检测培养液中VEGF蛋白水平,分析反义核酸对K562细胞的作用。结果:筛选出6条反义药物对K562细胞生长有明显抑制作用,均优于阳性对照组(X2)。与随机对照组(X1)相比,最优序列X7组细胞生长抑制率达31.9%、培养液中VEGF蛋白表达抑制率达51.4%,overall△G₃₇与反义药物活性密切相关(r=0.887,P<0.01)。结论:计算机辅助设计有助于获得更好反义药物,VEGF反义药物可抑制K562细胞生长及VEGF蛋白表达,内源性VEGF蛋白具有促进K562细胞增殖的功能。